Podocytes and Proteinuric Kidney Disease

Glomerular disease is the most common cause of endstage renal disease (ESRD), accounting for almost two thirds of cases. In glomerular disease, alterations of po-docytes are of particular importance. Podocyte loss represents a central mediator of glomerular sclerosis. Toxic, genetic, immune, infecti...

Full description

Bibliographic Details
Main Authors: Koroshi Alketa, Idrizi Alma
Format: Article
Language:English
Published: Sciendo 2015-02-01
Series:BANTAO Journal
Subjects:
Online Access:https://doi.org/10.2478/bj-2014-0004
id doaj-47d6f17f81034cf3983ea0204244fe56
record_format Article
spelling doaj-47d6f17f81034cf3983ea0204244fe562021-09-05T21:00:26ZengSciendoBANTAO Journal2451-31052015-02-01121161910.2478/bj-2014-0004Podocytes and Proteinuric Kidney DiseaseKoroshi AlketaIdrizi AlmaGlomerular disease is the most common cause of endstage renal disease (ESRD), accounting for almost two thirds of cases. In glomerular disease, alterations of po-docytes are of particular importance. Podocyte loss represents a central mediator of glomerular sclerosis. Toxic, genetic, immune, infectious, oxidant, metabolic, hemody-namic, and other mechanisms can all target the podo-cytes. These mechanisms provide new insight into the unique dynamic microenvironment that each individual podocyte inhabits and how it can turn hostile to survival. At the same time, they raise new therapeutic challenges to preserve glomerular function by containing podocyte injury and limiting its spread, both in podo-cytopathies and in other progressive glomerular diseases. Treatment strategies should aim at enhancing podocyte survival. The renin-angiotensin axis blockade, apart from its antifibrotic and intraglomerular hemodynamic effects, has an important role in preventing podocyte loss. However, only long-term observational studies can clarify if many patients will benefit from podocyte-targeted treatment such as abatacept or similar agents.https://doi.org/10.2478/bj-2014-0004podocytesglomeruliproteinuriaangioten-sin blockade
collection DOAJ
language English
format Article
sources DOAJ
author Koroshi Alketa
Idrizi Alma
spellingShingle Koroshi Alketa
Idrizi Alma
Podocytes and Proteinuric Kidney Disease
BANTAO Journal
podocytes
glomeruli
proteinuria
angioten-sin blockade
author_facet Koroshi Alketa
Idrizi Alma
author_sort Koroshi Alketa
title Podocytes and Proteinuric Kidney Disease
title_short Podocytes and Proteinuric Kidney Disease
title_full Podocytes and Proteinuric Kidney Disease
title_fullStr Podocytes and Proteinuric Kidney Disease
title_full_unstemmed Podocytes and Proteinuric Kidney Disease
title_sort podocytes and proteinuric kidney disease
publisher Sciendo
series BANTAO Journal
issn 2451-3105
publishDate 2015-02-01
description Glomerular disease is the most common cause of endstage renal disease (ESRD), accounting for almost two thirds of cases. In glomerular disease, alterations of po-docytes are of particular importance. Podocyte loss represents a central mediator of glomerular sclerosis. Toxic, genetic, immune, infectious, oxidant, metabolic, hemody-namic, and other mechanisms can all target the podo-cytes. These mechanisms provide new insight into the unique dynamic microenvironment that each individual podocyte inhabits and how it can turn hostile to survival. At the same time, they raise new therapeutic challenges to preserve glomerular function by containing podocyte injury and limiting its spread, both in podo-cytopathies and in other progressive glomerular diseases. Treatment strategies should aim at enhancing podocyte survival. The renin-angiotensin axis blockade, apart from its antifibrotic and intraglomerular hemodynamic effects, has an important role in preventing podocyte loss. However, only long-term observational studies can clarify if many patients will benefit from podocyte-targeted treatment such as abatacept or similar agents.
topic podocytes
glomeruli
proteinuria
angioten-sin blockade
url https://doi.org/10.2478/bj-2014-0004
work_keys_str_mv AT koroshialketa podocytesandproteinurickidneydisease
AT idrizialma podocytesandproteinurickidneydisease
_version_ 1717782943286427648